Omega Therapeutics, Inc. Common Stock
OMGA
OMGA was delisted on the 24th of February, 2025.
54 hedge funds and large institutions have $303M invested in Omega Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 6 reducing their positions, and 5 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
33% more call options, than puts
Call options by funds: $338K | Put options by funds: $255K
10% more funds holding
Funds holding: 49 → 54 (+5)
22% less capital invested
Capital invested by funds: $389M → $303M (-$86.2M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$23.1M |
| 2 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$6.02M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.7M |
| 4 |
6CM
683 Capital Management
New York
|
+$3.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$914K |
| 2 |
BlackRock
New York
|
-$186K |
| 3 |
Man Group
London,
United Kingdom
|
-$114K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$76K |
OMGA Hedge Fund Activity: Q1 2023 in Review
54 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q1 2023, worth a combined $303M — down 22% from $389M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new OMGA positions and 5 closed out — a net gain of 5 holders — while 27 added to existing stakes and 6 trimmed.
The largest buyer was Flagship Pioneering, adding an estimated $23.1M. The largest seller was Oasis Management Company, exiting entirely with an estimated $914K sold.
- 54 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q1 2023, up from 49 in Q4 2022.
- Funds reported $303M of Omega Therapeutics, Inc. Common Stock stock for Q1 2023, down 22% quarter-over-quarter.
- 10 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of +5 holders.
- The largest Omega Therapeutics, Inc. Common Stock buyer in Q1 2023 was Flagship Pioneering, an estimated $23.1M added.
- The largest Omega Therapeutics, Inc. Common Stock seller in Q1 2023 was Oasis Management Company, an estimated $914K sold.
Based on aggregated 13F filings for Q1 2023.